Replies to post #268893 on Avid Bioservices Inc (CDMO)

[vinmantoo]

Vin, immuno-oncology 2.0 is coming

Obviously.

I have never had a problem with anti-XYZ downstream agents. Yes, clearly they do work. But you seem to be still inside the Immuno-oncology 1.0 box, focusing only on solo therapy, as if that were the only approach, and the only stock to buy.

Not sure where you got that idea, but I have been a proponent of combination therapy for a while and stated so on this board several times.

Other investors are watching the major players involved in Immuno-oncology 2.0, and see the focus on combination therapy. Yes, downstream inhibitors work well for a minority of patients. That was the conclusion of I/O 1.0.

No, the conclusion is that single agent IOs works EXTREMELY well for a good percentage of the patients treated. Different of such single agents have been approved and are generating a lot of money for companies who own them, and for investors who own shares in those companies. Bavi, PPHM, and PPHM investors are not part of this group so have not shared in such monetary success.

If an investor believes I/O research is complete and 1.0 is as far as the field will go, well, then it would be correct to sink all funds into BMS and MRK.

Just please consider that others are following thought leaders in the field, and think I/O 2.0 heralds a different approach.

I don't believe that IOs as single agents are the end all, and the companies involved in such work do not either. There is a race going on to combine IOs which each show efficacy as single agents in the hopes of improving efficacy and showing enough synergy so that the dosages of the single agents can be reduced to lower side-effect profiles. Bavi is not a major player since it has failed in all trials so far. Sure PPHM is pushing it and hoping something will come out of it, but they are late to the game. They also have no money behind them to push it forward in the race, so are essentially bringing a water pistol with little to no water in it to a gun fight. Because of this, the odds are decidedly against it.

The focus of you and many people on this board has been on combinations of IOs. I feel what has been underemphasized is single agents IOs in combination with targeted anti-proliferative antibodies (e.g. Herceptin) or growth factors (e.g. tamoxifen or Xtandi) or with antibodies that specifically bind cancer cell antigens and have been shown to elicit efficacy own their own. That greatly expands the realm of single agent IOs that have shown efficacy on their own.

[Protector]

sualco about

But you seem to be still inside the Immuno-oncology 1.0 box, focusing only on solo therapy, as if that were the only approach, and the only stock to buy.

Not only is this a correct observation I would even say more:

The complete BIOTECH INDUSTRY agrees that mono-therapy was the step-up/step-in and that combination therapy will be what is needed and bring the better solutions.

Novartis CEO on CNBC, AstraZeneca in their new strategy PR announcing the end of their mono-therapy pipelines to concentrate on combination therapy, recently ROCHE announcing that it is all about the many interesting combinations, ...

Furthermore the merger and acquisition program are/were for a large part aimed at buying antibodies.

So yes, PD-1, PD-L1, CTLA-4 they have NO FUTURE in mono-therapy as the first combination that beats them will take ALL their SOC's away in no time.